The Swiss drugmaker will obtain rights to develop and commercialise therapeutic antibodies resulting from the collaboration, while AbCellera will receive payments for research and is eligible to receive clinical and regulatory milestone payments and royalties
AbCellera, Incyte partner to advance oncology antibodies. (Credit: Julia Koblitz on Unsplash)
Canadian biotech company AbCellera has entered a strategic collaboration with US-based biopharmaceutical company Incyte, to discover and develop therapeutic antibodies in oncology.
Under the terms of the agreement, the US drugmaker will obtain rights to develop and commercialise therapeutic antibodies resulting from the collaboration.
In exchange, AbCellera will receive payments for research and is eligible to receive downstream clinical and regulatory milestone payments and royalties on net sales of the products.
AbCellera senior vice president Murray McCutcheon said: “We are excited to partner with Incyte, which has a track record of developing first-in-class medicines and bringing them to patients in need.
“We look forward to working as an extension of Incyte’s team to address complex antibody discovery challenges and accelerate the development of Incyte’s preclinical pipeline of oncology medicines.”
AbCellera is a biotechnology company engaged in the research and development of human antibodies, transforming conventional antibody drug discovery.
It integrates expert teams, technology, and facilities with data science and automation to advance antibody-based medicines from target to clinic.
In March this year, AbCellera and RQ Bio they have entered a strategic collaboration to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio.
In June, the company entered a research collaboration with Confo Therapeutics, for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets.
Established in 2002, Incyte develops and manufactures prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity.
Earlier this year, the company announced that its ruxolitinib cream had met its primary endpoint in the Phase 3 TRuE-AD3 study of children with atopic dermatitis (AD).
Incyte biotherapeutics vice president Patrick Mayes said: “This collaboration supports our continued commitment to developing new therapeutics that may improve and expand treatment options for patients with cancer.
“We are excited to partner with AbCellera to initiate this research and look forward to collaborating with them to identify new antibody therapeutics that may address unmet needs in oncology.”